Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction (results of the ICTUS-AMI trial)
Background We investigated whether the effects of adjunctive therapy with intracoronary urokinase would be noninferior to those of intracoronary tirofiban in primary percutaneous coronary intervention (PCI) for patients with ST-elevation myocardial infarction (STEMI)Methods A total of 490 patients with acute STEMI undergoing primary PCI were randomized to intracoronary bolus of tirofiban (10 μg/kg; n=247) or urokinase (250 kU/20 ml; n=243).Levels of P-selectin, vWF, CD40L and serum amyloid A (SAA) in the coronary sinus were measured before and after intracoronary administration.The primary endpoint was the rate of complete (≥70％) ST-segment-resolution (STR) at 90 min post-intervention.We assumed a 59％ complete STR rate in the intracoronary tirofiban group, and the noninferiority margin was set to 15％.The secondary endpoints included corrected TIMI frame count (cTFC), left ventricular ejection fraction (LVEF), and major adverse cardiac events(MACE) at 6-month follow-up.
ZHU Tian-qi SHEN Wei-feng ZHANG Qi DING Feng-hua QIU Jian-ping JIN Hui-geng JIANG Li LU Lin ZHANG Rui-yan HU Jian
Rui Jin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China Gong Li Hospital Pudong New District,Shanghai China Putuo District Central Hospital,Shanghai,China Changning District Central Hospital,Shanghai,China
国内会议
北京
英文
4-4
2013-03-20（万方平台首次上网日期，不代表论文的发表时间）